ITC Ltd reports higher profits led by cigarette sales

Feb.07.2023
ITC Ltd reports higher profits led by cigarette sales
ITC Ltd reports higher-than-expected profits buoyed by strong cigarette sales and stable demand for packaged foods in India.

On Friday, ITC Ltd, a conglomerate in India, announced its quarterly profits which exceeded expectations due to strong cigarette sales, as well as stable demand for its packaged food products.


The business conglomerate, which operates in the tobacco and hotel industries, has announced a rise in profits for the October-December quarter. The profits have increased from 41.56 billion rupees to 50.31 billion rupees ($614 million) compared to the same period last year.


According to Refinitiv IBES, analysts predict that profits will increase to INR 47.44 billion (USD 573 million) on average.


ITC, which owns numerous brands including Sunfeast and Classmate, stated in a declaration that consumer sentiment has improved this quarter.


As commodity inflation continues to slow down, economic activity in India is gaining momentum.


ITC's overall operating revenue has increased by approximately 3%, reaching INR 172.65 billion ($2.08 billion), with over 40% of that coming from its cigarette business.


This business possesses the Classic and Gold Flake brands, with revenue growth of nearly 17% to 72.88 billion rupees.


This week in India, the cigarette industry is facing challenges in the wake of a potential 16% increase in taxes due to it being considered a national disaster. Some analysts believe that this could result in a "moderate" 1.5% increase in taxes. Others suggest that ITC should respond by raising prices.


ITC's fast-moving consumer goods (FMCG) business, which includes a combination of biscuits, noodles, snacks, and dairy products, has reported an 18% growth in revenue. The company plans to acquire Sproutlife Foods, the maker of Yoga Bars, to expand its nutrition-led health food business.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

South Korean convenience store GS25 and KT&G jointly released a new heated tobacco product, which will be available starting in October
South Korean convenience store GS25 and KT&G jointly released a new heated tobacco product, which will be available starting in October
South Korean convenience store chain GS25 has partnered with KT&G to launch a limited-edition heated tobacco device, the "Lil Hybrid 3.0 X GS25." A total of 48,000 units of the new device, featuring the GS25's signature blue, are available, targeting customers in their 20s and 30s. Each device is priced at approximately US$63 and is scheduled to be released in early October.
Sep.30 by 2FIRSTS.ai
UK Government Officially Confirms Vaping Products Duty and Stamps Scheme, Effective October 2026
UK Government Officially Confirms Vaping Products Duty and Stamps Scheme, Effective October 2026
HM Revenue & Customs (HMRC) has officially confirmed that the UK will implement a Vaping Products Duty (VPD) and Vaping Duty Stamps (VDS) scheme from October 1, 2026. The duty will apply to all vaping liquids at a flat rate of £2.20 per 10ml. Businesses must register for approval starting April 1, 2026. The stamps scheme will take effect in October 2026 with a six-month grace period, after which, from April 2027, unstamped products will be prohibited from sale.
Oct.02 by 2FIRSTS.ai
ASDF responds to Malaysia's proposed e-cigarette ban: Implementation prospects remain unclear; urges compliant operations and diversified strategies
ASDF responds to Malaysia's proposed e-cigarette ban: Implementation prospects remain unclear; urges compliant operations and diversified strategies
Regarding the Malaysian government's plan to implement a nationwide ban on the sale and use of e-cigarettes in phases from mid-2026, local e-cigarette brand ASDF told 2Firsts that this move reflects the government's concerns over public health, youth protection and market regulation. However, uncertainties remain regarding the specific implementation methods and pace of enforcement for the policy.
Sep.29
PMI Japan Unveils Limited-Edition IQOS ILUMA i “Galaxy Blue,” Priced Around $47
PMI Japan Unveils Limited-Edition IQOS ILUMA i “Galaxy Blue,” Priced Around $47
Philip Morris Japan announced it will release the limited-edition IQOS ILUMA i “Galaxy Blue” across IQOS stores nationwide starting October 29, priced at JPY 6,980 including tax (about USD 47). The new model features a space-themed design, with a members-only promotion to run at the Nagoya IQOS store.
Oct.29 by 2FIRSTS.ai
Russia Plans to Allow Regional Vape Sales Bans from September 2026
Russia Plans to Allow Regional Vape Sales Bans from September 2026
Russia’s Ministry of Finance (Минфин) has drafted amendments to an existing licensing bill that would grant regional authorities the power to ban retail sales of vapes and nicotine liquids from September 1, 2026, to September 1, 2031, RBC reported. Stores violating the ban would lose their tobacco retail licenses.
Nov.19 by 2FIRSTS.ai
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai